Awake craniotomy anesthetic management using dexmedetomidine, propofol, and remifentanil

Andrea Prontera,1 Stefano Baroni,2 Andrea Marudi,2 Franco Valzania,3 Alberto Feletti,1 Francesca Benuzzi,4 Elisabetta Bertellini,2 Giacomo Pavesi1 1Department of Neurosurgery, Nuovo Ospedale Civile SAgostino-Estense, 2Department of Anesthesiology, Nuovo Ospedale Civile SAgostino-Estense, 3Departmen...

Full description

Bibliographic Details
Main Authors: Prontera A, Baroni S, Marudi A, Valzania F, Feletti A, Benuzzi F, Bertellini E, Pavesi G
Format: Article
Language:English
Published: Dove Medical Press 2017-03-01
Series:Drug Design, Development and Therapy
Subjects:
Online Access:https://www.dovepress.com/awake-craniotomy-anesthetic-management-using-dexmedetomidine-propofol--peer-reviewed-article-DDDT
id doaj-562f0e1d5ee84ef5b21bace140fdd6fb
record_format Article
spelling doaj-562f0e1d5ee84ef5b21bace140fdd6fb2020-11-24T23:24:04ZengDove Medical PressDrug Design, Development and Therapy1177-88812017-03-01Volume1159359831678Awake craniotomy anesthetic management using dexmedetomidine, propofol, and remifentanilProntera ABaroni SMarudi AValzania FFeletti ABenuzzi FBertellini EPavesi GAndrea Prontera,1 Stefano Baroni,2 Andrea Marudi,2 Franco Valzania,3 Alberto Feletti,1 Francesca Benuzzi,4 Elisabetta Bertellini,2 Giacomo Pavesi1 1Department of Neurosurgery, Nuovo Ospedale Civile SAgostino-Estense, 2Department of Anesthesiology, Nuovo Ospedale Civile SAgostino-Estense, 3Department of Neurology, Nuovo Ospedale Civile S Agostino-Estense, 4Department of Neuroscience, University of Modena and Reggio Emilia, Modena, Italy Introduction: Awake craniotomy allows continuous monitoring of patients’ neurological functions during open surgery. Anesthesiologists have to sedate patients in a way so that they are compliant throughout the whole surgical procedure, nevertheless maintaining adequate analgesia and anxiolysis. Currently, the use of α2-receptor agonist dexmedetomidine as the primary hypnotic–sedative medication is increasing.Methods: Nine patients undergoing awake craniotomy were treated with refined monitored anesthesia care (MAC) protocol consisting of a combination of local anesthesia without scalp block, low-dose infusion of dexmedetomidine, propofol, and remifentanil, without the need of airways management.Results: The anesthetic protocol applied in our study has the advantage of decreasing the dose of each drug and thus reducing the occurrence of side effects. All patients had smooth and rapid awakenings. The brain remained relaxed during the entire procedure.Conclusion: In our experience, this protocol is safe and effective during awake brain surgery. Nevertheless, prospective randomized trials are necessary to confirm the optimal anesthetic technique to be used. Keywords: dexmedetomidine, awake surgery, anesthesiahttps://www.dovepress.com/awake-craniotomy-anesthetic-management-using-dexmedetomidine-propofol--peer-reviewed-article-DDDTDexmedetomidineAwake surgeryAnesthesia
collection DOAJ
language English
format Article
sources DOAJ
author Prontera A
Baroni S
Marudi A
Valzania F
Feletti A
Benuzzi F
Bertellini E
Pavesi G
spellingShingle Prontera A
Baroni S
Marudi A
Valzania F
Feletti A
Benuzzi F
Bertellini E
Pavesi G
Awake craniotomy anesthetic management using dexmedetomidine, propofol, and remifentanil
Drug Design, Development and Therapy
Dexmedetomidine
Awake surgery
Anesthesia
author_facet Prontera A
Baroni S
Marudi A
Valzania F
Feletti A
Benuzzi F
Bertellini E
Pavesi G
author_sort Prontera A
title Awake craniotomy anesthetic management using dexmedetomidine, propofol, and remifentanil
title_short Awake craniotomy anesthetic management using dexmedetomidine, propofol, and remifentanil
title_full Awake craniotomy anesthetic management using dexmedetomidine, propofol, and remifentanil
title_fullStr Awake craniotomy anesthetic management using dexmedetomidine, propofol, and remifentanil
title_full_unstemmed Awake craniotomy anesthetic management using dexmedetomidine, propofol, and remifentanil
title_sort awake craniotomy anesthetic management using dexmedetomidine, propofol, and remifentanil
publisher Dove Medical Press
series Drug Design, Development and Therapy
issn 1177-8881
publishDate 2017-03-01
description Andrea Prontera,1 Stefano Baroni,2 Andrea Marudi,2 Franco Valzania,3 Alberto Feletti,1 Francesca Benuzzi,4 Elisabetta Bertellini,2 Giacomo Pavesi1 1Department of Neurosurgery, Nuovo Ospedale Civile SAgostino-Estense, 2Department of Anesthesiology, Nuovo Ospedale Civile SAgostino-Estense, 3Department of Neurology, Nuovo Ospedale Civile S Agostino-Estense, 4Department of Neuroscience, University of Modena and Reggio Emilia, Modena, Italy Introduction: Awake craniotomy allows continuous monitoring of patients’ neurological functions during open surgery. Anesthesiologists have to sedate patients in a way so that they are compliant throughout the whole surgical procedure, nevertheless maintaining adequate analgesia and anxiolysis. Currently, the use of α2-receptor agonist dexmedetomidine as the primary hypnotic–sedative medication is increasing.Methods: Nine patients undergoing awake craniotomy were treated with refined monitored anesthesia care (MAC) protocol consisting of a combination of local anesthesia without scalp block, low-dose infusion of dexmedetomidine, propofol, and remifentanil, without the need of airways management.Results: The anesthetic protocol applied in our study has the advantage of decreasing the dose of each drug and thus reducing the occurrence of side effects. All patients had smooth and rapid awakenings. The brain remained relaxed during the entire procedure.Conclusion: In our experience, this protocol is safe and effective during awake brain surgery. Nevertheless, prospective randomized trials are necessary to confirm the optimal anesthetic technique to be used. Keywords: dexmedetomidine, awake surgery, anesthesia
topic Dexmedetomidine
Awake surgery
Anesthesia
url https://www.dovepress.com/awake-craniotomy-anesthetic-management-using-dexmedetomidine-propofol--peer-reviewed-article-DDDT
work_keys_str_mv AT pronteraa awakecraniotomyanestheticmanagementusingdexmedetomidinepropofolandremifentanil
AT baronis awakecraniotomyanestheticmanagementusingdexmedetomidinepropofolandremifentanil
AT marudia awakecraniotomyanestheticmanagementusingdexmedetomidinepropofolandremifentanil
AT valzaniaf awakecraniotomyanestheticmanagementusingdexmedetomidinepropofolandremifentanil
AT felettia awakecraniotomyanestheticmanagementusingdexmedetomidinepropofolandremifentanil
AT benuzzif awakecraniotomyanestheticmanagementusingdexmedetomidinepropofolandremifentanil
AT bertellinie awakecraniotomyanestheticmanagementusingdexmedetomidinepropofolandremifentanil
AT pavesig awakecraniotomyanestheticmanagementusingdexmedetomidinepropofolandremifentanil
_version_ 1725562012413460480